A recent open-label, randomized, controlled pilot study conducted in AD patients demonstrated that Lf administration (250 mg/d) for a total of 3 months could significantly improve cognitive function (7); this might be associated with its effects on the Akt/PTEN pathway, consequently affecting key inflammatory and oxidative stress players involved in AD pathology. The gene discussed is PTEN; the disease is Alzheimer disease.